Emily's Entourage
Emily Kramer-Golinkoff is a co-founder of Emily's Entourage, an organization dedicated to accelerating research and drug development for nonsense mutations of Cystic Fibrosis, where Emily provides leadership and fosters collaboration among stakeholders. Previously, at Penn Medicine, University of Pennsylvania Health System, Emily served in various roles, including Manager of Strategic Initiatives and Operations, where strategic goals for the Center for Digital Health were developed and community engagement was enhanced. As Project Manager, oversight of the Social Media and Health Innovation Lab was provided, establishing Penn Medicine as a leader in healthcare social media. Earlier positions included managing social media initiatives and serving as a Marketing Assistant within the Department of Surgery. Emily holds a Master of Bioethics and a Certificate in Clinical Ethics Mediation from the University of Pennsylvania School of Medicine, as well as a Bachelor of Arts in Communication from the University of Pennsylvania.
This person is not in the org chart
This person is not in any teams
Emily's Entourage
Emily's Entourage (EE) is an innovative 501(c)3 foundation that funds research for new treatments and a cure for individuals in the final 10% of the cystic fibrosis (CF) community that do not benefit from existing mutation-targeted therapies, including those with nonsense mutations. CF is a fatal genetic disease primarily affecting the lungs and digestive system. Founded by Emily Kramer-Golinkoff, a woman with advanced stage CF, and her devoted friends and family, the organization has been featured in national media, including the New York Times, STAT, CNN, People, and more. Since 2011, Emily’s Entourage has awarded millions of dollars in research grants, launched a now-acquired CF gene therapy company, developed a patient registry and clinical trial matchmaking program to accelerate clinical trial recruitment, and led worldwide efforts to drive high-impact research and drug development. The organization’s work is particularly critical now as revolutionary breakthroughs are available for roughly 90% of the CF population, but those in the outlying 10% that unfortunately do not benefit from these major advances. The work of EE is laser-focused on changing that — and doing it fast, so nobody is left behind